1h Free Analyst Time
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 5 and 8 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Immunology and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Lung Cancer, Metastatic Melanoma, Renal Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Follicular Lymphoma, Hepatitis B, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Ocular Melanoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Ulcerative Colitis and Uterine Cancer.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development
AbbVie Inc
Abeome Corp
Alligator Bioscience AB
Apogenix AG
BioInvent International AB
Bristol-Myers Squibb Co
Denceptor Therapeutics Ltd
GigaGen Inc
GlaxoSmithKline Plc
Incyte Corp
Innovent Biologics Inc
Invenra Inc
Johnson & Johnson
Kyowa Hakko Kirin Co Ltd
Pfizer Inc
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles
ABBV-368 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABM-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATOR-1015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Agonize FCGR2A, FCGR2B and TNFRSF4 for Methicillin-Resistant Staphylococcus aureus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Agonize TNFRSF4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3174998 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuOHX-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-1949 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-4083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize OX40 for Hematological Tumor and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize OX40 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OrthomAb - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04518600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-279252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2019: Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer
Apr 10, 2019: Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston
Mar 07, 2019: Alligator Bioscience: First patient dosed in phase I study of ATOR-1015
Feb 20, 2019: GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires
Feb 14, 2019: Innovent starts treatment in IBI101 monoclonal antibody trial
Dec 11, 2018: Alligator Bioscience starts clinical phase I study with ATOR-1015
Dec 04, 2018: Innovent receives an approval from the US FDA to initiate clinical trials for its Anti-OX40 Monoclonal Antibody IBI101
Jul 25, 2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101
Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation
Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015
Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015
Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4
Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1)
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Products under Development by Companies, H1 2019 (Contd..4), H1 2019
Products under Development by Companies, H1 2019 (Contd..5), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AbbVie Inc, H1 2019
Pipeline by Abeome Corp, H1 2019
Pipeline by Alligator Bioscience AB, H1 2019
Pipeline by Apogenix AG, H1 2019
Pipeline by BioInvent International AB, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Denceptor Therapeutics Ltd, H1 2019
Pipeline by GigaGen Inc, H1 2019
Pipeline by GlaxoSmithKline Plc, H1 2019
Pipeline by Incyte Corp, H1 2019
Pipeline by Innovent Biologics Inc, H1 2019
Pipeline by Invenra Inc, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019
Pipeline by Pfizer Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abeome Corp
- Alligator Bioscience AB
- Apogenix AG
- BioInvent International AB
- Bristol-Myers Squibb Co
- Denceptor Therapeutics Ltd
- GigaGen Inc
- GlaxoSmithKline Plc
- Incyte Corp
- Innovent Biologics Inc
- Invenra Inc
- Johnson & Johnson
- Kyowa Hakko Kirin Co Ltd
- Pfizer Inc
